|

Chiauranib Clinical Trials

1 actively recruiting trial

▼ -1 trial since July 2026

Also known as: CS2164

Pipeline

Phase 3: 1

Top Sponsors

  • Chipscreen Biosciences, Ltd.1

Indications

  • Chiauranib1
  • Relapsed or Refractory1
  • Paclitaxel1
  • Ovarian Cancer1
  • Cancer1

Other1 trial

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.